Features | VJDementia

Phase III EXERT trial: exercise shown to stall cognitive decline in patients with mild cognitive impairment

The Phase III, multicenter, randomized EXERT trial enrolled almost 300 patients to investigate the effects of regular exercise on brain…

Breakthrough in Alzheimer’s disease diagnosis: FDA authorizes diagnostic test for β-amyloid plaques

The U.S. Food and Drug Administration (FDA) has authorized the marketing of the Fujirebio’s Lumipulse G β-Amyloid Ratio (1-42/1-40) in…

New risk genes associated with Alzheimer’s disease identified

An exciting study published in Nature Genetics has doubled the number of genetic loci known to associate with Alzheimer’s disease,…

Highlights from ARUK 2022

The Alzheimer’s Research UK Conference was held in Brighton, UK, on 1-2 March 2022. Leading experts discussed the key topics…

Nasal vaccine for Alzheimer’s disease enters first-in-human trial

In recent years, there has been a greater interest in gaining further insight into the relationship between Alzheimer’s disease (AD)…

Potential new therapies for Alzheimer’s disease to look out for in 2022: anti-amyloid-β antibodies

The number of individuals worldwide with Alzheimer’s disease is growing at a rapid rate. Therefore, new treatments are urgently needed….

The Phase II/III GAIN Trial: atuzaginstat for mild-moderate Alzheimer’s disease

Atuzaginstat, a novel small-molecule bacterial protease lysine gingipain inhibitor, is currently under investigation as a first-in-class treatment to slow or…

Novel antibody donanemab receives FDA breakthrough designation for Alzheimer’s disease

A hallmark feature of Alzheimer’s disease (AD) is the aggregation of amyloid-β (Aβ). Although many trials have been conducted aiming…